366 related articles for article (PubMed ID: 11185891)
1. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
3. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
4. Characteristic expression of globotriaosyl ceramide in human ovarian carcinoma-derived cells with anticancer drug resistance.
Kiguchi K; Iwamori Y; Suzuki N; Kobayashi Y; Ishizuka B; Ishiwata I; Kita T; Kikuchi Y; Iwamori M
Cancer Sci; 2006 Dec; 97(12):1321-6. PubMed ID: 16995873
[TBL] [Abstract][Full Text] [Related]
5. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
6. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
7. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
8. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Yamamoto K; Kikuchi Y; Kudoh K; Nagata I
J Cancer Res Clin Oncol; 2000 Mar; 126(3):168-72. PubMed ID: 10741911
[TBL] [Abstract][Full Text] [Related]
10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
11. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
13. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Frankel A; Buckman R; Kerbel RS
Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
[TBL] [Abstract][Full Text] [Related]
15. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
17. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Yen WC; Corpuz MR; Prudente RY; Cooke TA; Bissonnette RP; Negro-Vilar A; Lamph WW
Clin Cancer Res; 2004 Dec; 10(24):8656-64. PubMed ID: 15623650
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy of paclitaxel followed by nedaplatin for human ovarian cancer].
Uchida N; Yamada H; Maekawa R; Yoshioka T
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1943-9. PubMed ID: 12465394
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
20. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies.
Rose WC
J Natl Cancer Inst Monogr; 1993; (15):47-53. PubMed ID: 7912529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]